Author: kodiac

  • Agmatine

    Plain-language summaryIntrigue 55 / 100

    Agmatine is a naturally occurring small molecule made in the body from arginine. It modulates several systems including NMDA receptors, nitric oxide, and imidazoline receptors. Used as a supplement for nerve pain and mood. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Endogenous polyamine neuromodulator with multi-target activity at NMDA receptors, imidazoline receptors, alpha-2 adrenoceptors, and nitric oxide synthase

    A decarboxylated arginine metabolite and endogenous neuromodulator distinguished by concurrent NMDA receptor channel blockade, imidazoline receptor agonism, selective inducible nitric oxide synthase inhibition, and alpha-2 adrenoceptor activation, with emerging clinical evidence in neuropathic pain, depression, and neuroprotection.

    Abstract

    Agmatine (4-aminobutylguanidine) is an endogenous cationic amine produced by the decarboxylation of L-arginine via the mitochondrial enzyme arginine decarboxylase. First isolated in 1910 by the Nobel laureate Albrecht Kossel from herring sperm protamine hydrolysates, agmatine was rediscovered in 1994 as an endogenous mammalian neuromodulator synthesized, stored in synaptic vesicles, and released in a calcium-dependent manner from neurons in the hippocampus, hypothalamus, locus coeruleus, and other brain regions. The compound operates through a pharmacologically unusual multi-target profile: it produces voltage-dependent blockade of NMDA receptor-gated cation channels at an intrachannel pore site (IC50 approximately 300 micromolar); it binds with high affinity to imidazoline I1 receptors (Kd approximately 0.7 micromolar) and I2 receptors (Kd approximately 1 micromolar); it activates alpha-2 adrenoceptors (Kd approximately 4 micromolar); and it competitively inhibits inducible nitric oxide synthase (Ki approximately 220 micromolar) with selectivity over the neuronal and endothelial isoforms. This composite mechanism produces neuroprotective, analgesic, antidepressant, and anti-inflammatory activity across a broad range of preclinical models, including excitotoxic and ischemic neuronal injury, traumatic brain injury, neuropathic and inflammatory pain, and behavioral models of depression and anxiety.

    Clinical evidence, though still early-phase and limited in scale, has demonstrated efficacy of oral agmatine sulfate in lumbar disc-associated radiculopathy in a randomized, double-blind, placebo-controlled trial at 2,670 mg per day for 14 days, with statistically significant pain reduction versus placebo [1]. A pilot open-label case series in painful small fiber neuropathy reported approximately 46 percent mean pain reduction over two months at the same dose [2]. A 2026 prospective open-label case series at Massachusetts General Hospital reported preliminary evidence for agmatine sulfate augmentation in treatment-resistant obsessive-compulsive disorder, with 40 percent of patients achieving clinically meaningful improvement on the Yale-Brown Obsessive Compulsive Scale [3]. Preclinical antidepressant-like activity has been demonstrated in the forced swimming test and tail suspension test across multiple laboratories, mediated through NMDA receptor blockade, nitric oxide synthase inhibition, and AMPA receptor and mTOR signaling activation. The compound modulates opioid pharmacology in a biphasic manner: it potentiates acute morphine analgesia while preventing the development of analgesic tolerance and physical dependence, a profile that has attracted substantial research interest in the context of the opioid crisis.

    Safety data are favorable. A long-term safety case report documented 5 years of continuous daily intake at 2.67 g agmatine sulfate with no adverse events, and postmarketing surveillance of 1,015 individuals consuming the same regimen for periods of 3 weeks to 3 years identified no adverse events [4]. Clinical trial adverse events have been limited to mild, transient gastrointestinal symptoms (nausea, diarrhea, abdominal discomfort) at the highest studied doses. The compound is commercially available as a dietary supplement (agmatine sulfate) in multiple jurisdictions. This monograph reviews the chemistry, biosynthesis, and multi-target pharmacology of agmatine; the pharmacokinetic profile including oral bioavailability and CNS distribution; the preclinical and clinical evidence base across neuropathic pain, depression, neuroprotection, and opioid modulation; sourcing and quality considerations; reconstitution and handling; stack interactions; adverse-event signal; and a comparative assessment of five mechanistically related compounds against agmatine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-075Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Anastrozole

    Plain-language summaryIntrigue 65 / 100

    Anastrozole (Arimidex) is a third-generation aromatase inhibitor approved in 1995, first-line for postmenopausal hormone-receptor-positive breast cancer. It blocks the aromatase enzyme, which converts androgens (including testosterone) into estrogens. At the standard 1 mg daily dose, it lowers plasma estradiol by about 80 percent. In breast cancer this slows or shrinks estrogen-driven tumors. Off-label, low doses are used by anabolic steroid users to control estrogen conversion and prevent gynecomastia. Side effects include joint stiffness and accelerated bone loss (because estrogen is essential for bone in both sexes). The ATAC trial established its superiority over tamoxifen in postmenopausal women. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Third-generation nonsteroidal aromatase inhibitor (triazole derivative)

    A potent, selective, reversible nonsteroidal aromatase inhibitor developed at Zeneca Pharmaceuticals for the adjuvant treatment of estrogen receptor-positive breast cancer, distinguished from steroidal inactivators by triazole-mediated competitive binding, oral bioavailability, and a long terminal half-life permitting once-daily dosing.

    Abstract

    Anastrozole (ZD1033, Arimidex) is a third-generation nonsteroidal aromatase inhibitor of the triazole class that selectively and reversibly inhibits the cytochrome P450 19A1 (CYP19A1, aromatase) enzyme complex responsible for the terminal step in estrogen biosynthesis: the conversion of androstenedione to estrone and testosterone to estradiol. At the approved oral dose of 1 mg once daily, anastrozole achieves greater than 96 percent suppression of plasma estradiol in postmenopausal women and approximately 97 percent inhibition of whole-body aromatase activity, without measurable effects on adrenocortical steroidogenesis, aldosterone production, or thyroid function. The compound was developed at Zeneca Pharmaceuticals (now AstraZeneca) through systematic optimization of triazole-bearing aromatase inhibitor scaffolds and received United States Food and Drug Administration approval in 1995 for the treatment of advanced breast cancer in postmenopausal women following tamoxifen therapy, with subsequent label expansions to first-line advanced disease (2000) and adjuvant treatment of early-stage hormone receptor-positive breast cancer (2002).

    The pivotal Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, enrolling 9,366 postmenopausal women with early-stage invasive breast cancer, established anastrozole as superior to tamoxifen on disease-free survival, time to recurrence, time to distant recurrence, and incidence of contralateral breast cancer at 100-month and 10-year analyses, with a carryover benefit extending beyond the 5-year treatment period. The International Breast Cancer Intervention Study II (IBIS-II) subsequently demonstrated a 49 percent reduction in breast cancer incidence in high-risk postmenopausal women receiving anastrozole 1 mg daily for 5 years compared to placebo, with a persistent preventive effect beyond the active treatment period at 131 months of median follow-up. Anastrozole is now among the most widely prescribed endocrine therapies in oncology, with established roles in adjuvant, neoadjuvant, extended adjuvant, and chemoprevention settings for estrogen receptor-positive breast cancer.

    Pharmacokinetics are characterized by rapid oral absorption (time to peak concentration approximately 2 hours), high oral bioavailability (approximately 85 percent), extensive hepatic metabolism through N-dealkylation, hydroxylation, and glucuronidation (with a principal inactive triazole metabolite), and a long terminal elimination half-life of 40 to 50 hours that supports once-daily dosing and achieves steady-state plasma concentrations within approximately 7 days. Anastrozole is not a potent inhibitor or inducer of cytochrome P450 enzymes at therapeutic concentrations, and clinically significant drug-drug interactions are uncommon. The compound is well tolerated; the principal adverse events are hot flashes, arthralgia, fatigue, and musculoskeletal stiffness, with the most clinically significant long-term safety signal being accelerated bone mineral density loss and increased fracture risk attributable to profound estrogen suppression, managed in clinical practice through concurrent bisphosphonate therapy and bone density monitoring.

    Beyond the oncology indication, anastrozole has been investigated as an off-label research tool for modulating the hypothalamic-pituitary-gonadal axis in males, where aromatase inhibition reduces the conversion of testosterone to estradiol, relieves estrogen-mediated negative feedback on gonadotropin secretion, and increases endogenous testosterone production. This application remains investigational and is not approved by regulatory authorities. This monograph reviews the chemistry, synthesis, and structural class of anastrozole; the molecular pharmacology of aromatase inhibition; the comprehensive pharmacokinetic record; preclinical pharmacology; the clinical evidence base across adjuvant, neoadjuvant, chemoprevention, and investigational indications; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signals; and a comparative assessment of five alternative aromatase-modulating agents against anastrozole on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-276Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • ACE-031

    Plain-language summaryIntrigue 60 / 100

    ACE-031 is a soluble decoy receptor designed to soak up myostatin (the molecular brake on muscle growth) and related TGF-beta family ligands before they can engage real receptors on muscle. Built as a fusion of the activin receptor type IIB extracellular domain with an antibody Fc tail for half-life extension, it was developed at Acceleron Pharma for muscular dystrophy. Phase 1 and 2 trials demonstrated meaningful muscle mass increases but were halted in 2013 because of safety signals (epistaxis and gum bleeding, suggesting off-target effects on related TGF-beta ligands involved in vascular biology). The myostatin-trap concept lives on in related compounds. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Soluble activin receptor type IIB-Fc fusion protein (ActRIIB-IgG1 ligand trap) targeting myostatin and TGF-beta superfamily signaling

    A recombinant soluble decoy receptor comprising the extracellular domain of human activin receptor type IIB fused to the Fc domain of human immunoglobulin G1, developed by Acceleron Pharma as a systemic ligand trap for myostatin and related TGF-beta superfamily negative regulators of skeletal muscle mass.

    Abstract

    ACE-031 is a recombinant fusion protein composed of the extracellular domain of human activin receptor type IIB (ActRIIB) linked to the Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1), engineered to function as a circulating soluble decoy receptor that intercepts and neutralizes myostatin (growth and differentiation factor 8, GDF-8), activin A, activin B, GDF-11, and other transforming growth factor-beta (TGF-beta) superfamily ligands before they can engage their endogenous cell-surface receptors and transduce downstream Smad2/3-dependent signaling that constrains skeletal muscle growth. Developed by Acceleron Pharma (Cambridge, Massachusetts), ACE-031 was the first ActRIIB-Fc fusion protein to enter clinical trials in humans and the first systemic ligand trap approach to be tested in Duchenne muscular dystrophy (DMD), representing a pharmacological strategy that targets not a single ligand but the convergent signaling node through which multiple negative regulators of muscle mass operate.

    The foundational preclinical work was established by Lee and McPherron (2001) and Lee et al. (2005), who demonstrated that a soluble form of ActRIIB produced dramatic skeletal muscle hypertrophy in wild-type mice and caused additive muscle gains even in myostatin-null animals, indicating that ligands beyond myostatin contribute to muscle mass regulation through the ActRIIB pathway. Acceleron subsequently developed ACE-031 as a pharmaceutical-grade recombinant protein and advanced it through preclinical studies in mice and non-human primates that demonstrated robust increases in lean body mass, thigh muscle volume, individual muscle fiber cross-sectional area, and ex vivo contractile force, with concurrent improvements in bone mineral density and favorable effects on fat metabolism. A Phase 1 single ascending-dose study in 48 healthy postmenopausal women (Attie et al., 2013, Muscle and Nerve) established linear pharmacokinetics with a mean terminal half-life of 10 to 15 days, demonstrated statistically significant increases of 3.3 percent in total body lean mass and 5.1 percent in thigh muscle volume at the 3 mg/kg dose after a single subcutaneous injection, and characterized a favorable acute safety profile.

    The clinical development program advanced to a Phase 2 randomized, double-blind, placebo-controlled, ascending-dose trial in ambulatory, corticosteroid-treated boys with DMD (Campbell et al., 2017, Muscle and Nerve). The trial demonstrated trends toward increased lean body mass, increased bone mineral density, reduced fat mass, and maintenance of six-minute walk test distance in the ACE-031 groups compared to placebo, but was terminated after the second dosing cohort because of emergent vascular safety signals: epistaxis in 25 percent and mucocutaneous telangiectasias in approximately 21 percent of treated subjects. These events were subsequently attributed to the broad ligand-trapping profile of the unmodified ActRIIB extracellular domain, specifically the sequestration of bone morphogenetic proteins 9 and 10 (BMP9 and BMP10), which are critical regulators of endothelial cell homeostasis and vascular integrity. In May 2013, Acceleron Pharma and Shire PLC concluded their collaboration and announced they would not restart development of ACE-031.

    The program’s discontinuation catalyzed two productive lines of successor development. Acceleron developed ACE-083, a follistatin-Fc fusion protein designed for local intramuscular injection that does not bind BMP9 or BMP10 and thus avoids the vascular signal. In parallel, the company developed luspatercept (ACE-536), a modified ActRIIB-Fc molecule with engineered ligand selectivity that avoids activin A and BMP trapping while retaining GDF-11 and GDF-8 neutralization, subsequently approved by the United States Food and Drug Administration for myelodysplastic syndrome-associated anemia and transfusion-dependent beta-thalassemia. ACE-031 itself is not approved by any regulatory authority for any indication. It remains available as a research-grade recombinant protein from chemical suppliers for in vitro and in vivo investigation of TGF-beta superfamily signaling, myostatin pathway biology, and muscle wasting pharmacology. Investigators should obtain analytical confirmation of identity, purity, and biological activity on every lot. This monograph documents the chemistry, mechanism of action, pharmacokinetics, preclinical pharmacology, clinical evidence, sourcing, handling, stack interactions, adverse-event profile, and comparative positioning of ACE-031 against five alternative myostatin/activin pathway inhibitors.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-358Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • 5-MeO-DMT

    Plain-language summaryIntrigue 76 / 100

    5-MeO-DMT is a tryptamine psychedelic chemically related to DMT but with strikingly different pharmacology: it prefers the 5-HT1A receptor over 5-HT2A, the opposite of N,N-DMT, which produces a qualitatively distinct experience generally described as an undifferentiated state rather than the visionary content of classical psychedelics. It is concentrated in the parotoid gland secretions of the Sonoran Desert toad (Bufo alvarius), the source of toad medicine ceremonies, and is found in several plants used in South American snuffs. Clinical interest in single-dose treatment for depression and substance use disorders is growing, with several small studies underway. The intensity and brevity of the experience pose unusual clinical and safety challenges. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Indolealkylamine tryptamine psychedelic with preferential 5-HT1A receptor agonism and broad serotonergic activity

    A naturally occurring 5-methoxy-substituted tryptamine distinguished from classical psychedelics by preferential high-affinity 5-HT1A receptor agonism, ultra-short duration of action, and emerging Phase 2 clinical evidence in treatment-resistant depression.

    Abstract

    5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT; CAS 1019-45-0; molecular formula C13H18N2O; molecular weight 218.30 g/mol) is a naturally occurring indolealkylamine tryptamine psychedelic first synthesized by Hoshino and Shimodaira in 1936, subsequently identified as a constituent of Anadenanthera peregrina seeds, Virola species bark resins, and the parotoid gland secretions of the Sonoran Desert toad Incilius alvarius (formerly Bufo alvarius). The compound is pharmacologically distinguished from other tryptamine psychedelics (N,N-dimethyltryptamine, psilocin, bufotenine) by a receptor binding profile that strongly favors the serotonin 5-HT1A receptor (Ki approximately 1.9 to 3 nM) over the 5-HT2A receptor (Ki approximately 900 nM), producing a 300- to 1000-fold selectivity ratio that inverts the binding preference of the classical 5-HT2A-preferring psychedelics. Functional pharmacology demonstrates full agonist activity at 5-HT1A receptors and partial to full agonism at 5-HT2A receptors, with additional binding at the serotonin transporter (SERT), sigma-1 receptors, and trace amine-associated receptor 1 (TAAR1).

    The subjective psychedelic experience produced by inhaled 5-MeO-DMT is characterized by a rapid onset (30 to 60 seconds), intense peak (5 to 15 minutes), and brief total duration (15 to 20 minutes), rendering the compound the shortest-acting of the classical tryptamine psychedelics. The ultra-short duration and the predominance of 5-HT1A-mediated pharmacology produce qualitative differences from 5-HT2A-preferring psychedelics: less visual perceptual distortion, more ego-dissolution and dissociative phenomenology, and high scores on mystical experience questionnaires comparable to high-dose psilocybin.

    Metabolism proceeds through two principal pathways. Monoamine oxidase A (MAO-A) catalyzes oxidative deamination to 5-methoxyindoleacetic acid, the primary inactivation route that accounts for the rapid systemic clearance and the oral inactivity of the compound in the absence of MAO inhibition. Cytochrome P450 2D6 (CYP2D6) catalyzes O-demethylation to bufotenine (5-hydroxy-N,N-dimethyltryptamine), a pharmacologically active metabolite with preferential 5-HT2A receptor affinity. CYP2D6 polymorphism substantially modulates the bufotenine metabolic fraction; poor metabolizers produce less bufotenine but experience prolonged parent compound exposure, while ultrarapid metabolizers generate more bufotenine with potential for additive serotonergic burden. The dual-enzyme metabolic architecture creates clinically significant drug-drug interactions, most critically with MAO inhibitors (harmine, harmaline, moclobemide, phenelzine, tranylcypromine), which increase 5-MeO-DMT systemic exposure 3.6- to 4.4-fold and bufotenine exposure 6.1- to 9.9-fold, with documented risk of serotonin toxicity and fatalities.

    Clinical development is led by GH Research (Dublin), whose inhalable mebufotenin formulation GH001 met the primary endpoint in a randomized, double-blind, placebo-controlled Phase 2b trial in 81 patients with treatment-resistant depression (TRD), demonstrating a placebo-adjusted Montgomery-Asberg Depression Rating Scale (MADRS) reduction of 15.5 points at day 8 and remission rates of 77.8 percent at 6 months in the open-label extension (announced February 2025). A Phase 1/2 open-label trial (Reckweg et al. 2023) in 12 TRD patients reported 87.5 percent remission at day 7 and no serious adverse events. Preclinical pharmacology demonstrates neuroplasticity effects including increased dendritic spine density in mouse medial frontal cortex, increased neurogenesis in the dentate gyrus, and anxiolytic effects in stressed animal models. The compound is classified as Schedule I in the United States, is not approved by any regulatory authority for medical use, and all research applications are subject to controlled substance research licensure. This monograph reviews the chemistry, natural occurrence, dual-enzyme metabolism, receptor pharmacology, pharmacokinetics, preclinical and clinical evidence, safety signal, sourcing, reconstitution, stack interactions, and a comparative assessment of five tryptamine psychedelic candidates against 5-MeO-DMT on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-341Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Allopregnanolone

    Plain-language summaryIntrigue 80 / 100

    Allopregnanolone is a neurosteroid metabolite of progesterone that powerfully potentiates GABA-A receptors. Recombinant allopregnanolone (brexanolone) is FDA-approved for postpartum depression. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Endogenous neurosteroid and positive allosteric modulator of GABA-A receptors with dual synaptic and extrasynaptic activity

    An endogenous pregnane neurosteroid and the most potent known positive allosteric modulator of GABA-A receptors, reduced to clinical practice as brexanolone (Zulresso) for postpartum depression and serving as the pharmacophore template for the orally bioavailable derivative zuranolone.

    Abstract

    Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one; 3alpha,5alpha-tetrahydroprogesterone; brexanolone) is an endogenous C21 pregnane neurosteroid biosynthesized from progesterone by sequential 5alpha-reductase and 3alpha-hydroxysteroid oxidoreductase activity in the central nervous system, adrenal cortex, ovary, and placenta. First isolated from adrenal tissue in 1938 and identified as a potent positive allosteric modulator of GABA-A receptors by Majewska and colleagues in 1986, allopregnanolone occupies a singular position in neuropsychopharmacology as the most potent endogenous modulator of inhibitory GABAergic neurotransmission. At low nanomolar concentrations, the compound allosterically enhances GABA-gated chloride currents at both synaptic (alpha-beta-gamma-containing) and extrasynaptic (alpha-beta-delta-containing) GABA-A receptor subtypes; at higher micromolar concentrations, it directly gates the chloride channel in the absence of GABA. The extrasynaptic receptor preference distinguishes allopregnanolone from benzodiazepines and underlies its characteristic anxiolytic, anticonvulsant, sedative-hypnotic, and antidepressant pharmacology.

    The translational trajectory of allopregnanolone spans more than eight decades. Selye reported the anesthetic properties of pregnane steroids in 1941. Baulieu and colleagues proposed the “neurosteroid” concept in 1981 after demonstrating de novo brain synthesis independent of peripheral endocrine sources. Majewska et al. (1986) established the GABA-A receptor mechanism. Paul and Purdy (1992) coined “neuroactive steroid” to encompass synthetic analogs acting through non-genomic receptor modulation. The modern clinical program began at Sage Therapeutics, which developed an intravenous formulation of synthetic allopregnanolone (designated SAGE-547, later brexanolone) for postpartum depression (PPD). Two Phase 3 randomized, double-blind, placebo-controlled trials (Meltzer-Brody et al. 2018) demonstrated rapid, clinically meaningful, and sustained reductions in Hamilton Depression Rating Scale (HAM-D) scores following a 60-hour continuous intravenous infusion. The United States Food and Drug Administration approved brexanolone (Zulresso) in March 2019 as the first therapy specifically indicated for PPD, subject to a Risk Evaluation and Mitigation Strategy (REMS) program requiring inpatient administration with continuous pulse oximetry monitoring owing to the risks of excessive sedation and loss of consciousness.

    A parallel clinical program led by Roberta Diaz Brinton at the University of Arizona has investigated allopregnanolone as a regenerative therapeutic for Alzheimer’s disease, grounded in preclinical demonstrations that the compound promotes hippocampal neural stem cell proliferation, neurogenesis, oligogenesis, and restoration of cognitive function in transgenic Alzheimer’s models and wild-type aged mice. A Phase 1b/2a multiple ascending dose trial (NCT02221622) in early Alzheimer’s disease reported safety, tolerability, and exploratory neuroimaging signals including preservation of hippocampal volume and functional connectivity changes after 12 weeks of intermittent intravenous dosing. Additional clinical investigations have evaluated allopregnanolone in fragile X-associated tremor/ataxia syndrome (FXTAS), status epilepticus, traumatic brain injury, and essential tremor.

    The principal pharmacokinetic limitation of endogenous allopregnanolone is negligible oral bioavailability (less than 5 percent), necessitating intravenous, subcutaneous, or intramuscular administration. This limitation drove development of orally bioavailable synthetic analogs, most notably zuranolone (SAGE-217), a deuterated allopregnanolone analog approved by the FDA in August 2023 for PPD, and ganaxolone (3beta-methyl allopregnanolone), approved for seizures associated with CDKL5 deficiency disorder in March 2022. Allopregnanolone is metabolized by extra-hepatic non-CYP pathways, principally keto-reduction, glucuronidation, and sulfation, with an elimination half-life of approximately 9 hours after intravenous infusion, a volume of distribution of approximately 3 L/kg, and greater than 99 percent plasma protein binding. The compound is a controlled substance (Schedule IV in the United States). This monograph reviews the chemistry, biosynthesis, receptor pharmacology, pharmacokinetics, preclinical and clinical evidence base across all studied indications, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event profile, and a structured comparative assessment of five neurosteroid GABA-A receptor modulators against allopregnanolone on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-159Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Amphetamine

    Plain-language summaryIntrigue 75 / 100

    Amphetamine is the prototype phenethylamine stimulant and the foundational compound for an entire pharmacological class. First synthesized in 1887 and developed clinically as Benzedrine in the 1930s, it works by reversing the transporters that normally pull dopamine, norepinephrine, and serotonin out of the synapse. Instead of inhibiting reuptake, it forces these neurotransmitters to flow outward, raising synaptic levels. Sold as Adderall (mixed salts), Dexedrine, and Evekeo for ADHD and narcolepsy. The two enantiomers behave differently: d-amphetamine is more dopaminergic and CNS-focused, l-amphetamine has stronger peripheral norepinephrine effects. Schedule II in the US with significant abuse potential. The canonical monoamine releaser in pharmacology research and a reference point for nearly every later phenethylamine. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Phenethylamine-class sympathomimetic monoamine-releasing agent with activity at the dopamine transporter, norepinephrine transporter, vesicular monoamine transporter 2, and trace amine-associated receptor 1

    A racemic or enantiopure phenylpropylamine first synthesized in 1887, developed as the prototypical indirect sympathomimetic stimulant, and established as a first-line pharmacotherapy for attention-deficit/hyperactivity disorder and narcolepsy through potent reversal of monoamine transporter function and vesicular monoamine redistribution.

    Abstract

    Amphetamine (alpha-methylphenethylamine) is the prototypical phenethylamine-class sympathomimetic amine and the most extensively characterized indirect monoamine-releasing agent in clinical neuropharmacology. First synthesized by Lazar Edeleanu in 1887 at the University of Berlin and pharmacologically characterized by Gordon Alles in 1927, amphetamine entered clinical medicine in 1933 as the Benzedrine inhaler for nasal congestion and was subsequently developed for narcolepsy, depression, obesity, and, from the 1960s onward, attention-deficit/hyperactivity disorder (ADHD). The compound acts principally by reversing the direction of the plasma membrane dopamine transporter (DAT) and norepinephrine transporter (NET), producing non-exocytotic efflux of cytoplasmic dopamine and norepinephrine into the synaptic cleft; by inhibiting vesicular monoamine transporter 2 (VMAT2), redistributing vesicular monoamine stores into the cytosol; and by activating the intracellular trace amine-associated receptor 1 (TAAR1), which modulates transporter phosphorylation state and downstream signaling cascades. Secondary mechanisms include weak inhibition of monoamine oxidase and modest serotonin transporter (SERT) reversal at higher concentrations. The net pharmacological effect is a robust increase in synaptic dopamine and norepinephrine concentrations in the prefrontal cortex, striatum, and nucleus accumbens, producing the characteristic profile of enhanced attention, executive function, wakefulness, locomotor activation, and appetite suppression.

    Pharmacokinetics are characterized by high oral bioavailability (approximately 75 to 100 percent depending on gastrointestinal pH and formulation), a plasma elimination half-life of approximately 10 hours for dextroamphetamine and 13 hours for levoamphetamine in adults, hepatic metabolism through cytochrome P450 2D6 (CYP2D6) hydroxylation and flavin-containing monooxygenase 3 (FMO3) N-oxidation, and pH-dependent renal excretion of unchanged drug. The two enantiomers exhibit differential potency: dextroamphetamine (the S-enantiomer) is approximately three to five times more potent than levoamphetamine (the R-enantiomer) at dopaminergic targets, while levoamphetamine retains relatively greater noradrenergic potency. Commercial formulations exploit this differential through racemic mixtures (mixed amphetamine salts), enantiopure dextroamphetamine preparations, and the prodrug lisdexamfetamine.

    The clinical evidence base for amphetamine in ADHD is among the largest in psychopharmacology. The 2018 Lancet Psychiatry network meta-analysis of 133 randomized controlled trials encompassing over 10,000 adult participants identified amphetamines as the most efficacious pharmacotherapy for ADHD in adults, with standardized mean differences on core symptom scales exceeding those of methylphenidate, atomoxetine, modafinil, and bupropion. In children and adolescents, amphetamines demonstrated the largest effect sizes on clinician-rated symptom measures among all studied agents. The compound is additionally approved for narcolepsy type 1 and has been investigated in treatment-resistant depression, traumatic brain injury-related cognitive dysfunction, and obesity.

    The safety profile at therapeutic doses is well characterized. Common adverse events include appetite suppression, insomnia, dry mouth, tachycardia, and modest systolic blood pressure elevation. Cardiovascular risk at therapeutic doses in individuals without structural heart disease is low, as demonstrated by multiple large pharmacoepidemiologic cohort studies. The principal long-term concern is the reinforcing properties of amphetamine mediated by mesolimbic dopamine signaling, which confer abuse liability; all amphetamine formulations carry a Schedule II controlled substance classification under the United States Controlled Substances Act. This monograph reviews the chemistry, stereochemistry, and synthesis of amphetamine; the multi-target molecular pharmacology including DAT, NET, VMAT2, and TAAR1 mechanisms; comprehensive pharmacokinetics; preclinical behavioral and neurochemical pharmacology; the clinical evidence base across ADHD, narcolepsy, and investigational indications; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety signals; and a comparative assessment of five alternative agents (methylphenidate, lisdexamfetamine, atomoxetine, modafinil, guanfacine) against amphetamine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-378Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Agomelatine

    Plain-language summaryIntrigue 68 / 100

    Agomelatine is an antidepressant that combines melatonin receptor activation (sleep regulation) with 5-HT2C antagonism (mood). FDA declined approval; widely used in Europe under the brand Valdoxan. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Melatonergic MT1/MT2 receptor agonist with serotonin 5-HT2C receptor antagonism

    A naphthalenic melatonin analog developed at Servier as the first non-monoaminergic antidepressant, distinguished by dual melatonergic agonism and serotonin 5-HT2C antagonism that resynchronizes disrupted circadian rhythms while enhancing frontocortical dopaminergic and noradrenergic transmission.

    Abstract

    Agomelatine (S 20098) is a naphthalenic analog of melatonin and the first clinically approved antidepressant whose mechanism of action does not rely on direct modulation of monoamine reuptake or degradation. Developed by Servier Laboratories and granted European marketing authorization in 2009 under the trade names Valdoxan and Thymanax, agomelatine acts through high-affinity agonism at the melatonin MT1 and MT2 G-protein-coupled receptors (Ki approximately 0.1 nanomolar) combined with neutral antagonism at the serotonin 5-HT2C receptor (Ki approximately 630 nanomolar), a pharmacological profile that is unique among marketed antidepressants and that produces a synergistic downstream effect on circadian rhythm resynchronization, frontocortical dopamine and norepinephrine release, hippocampal neurogenesis, and brain-derived neurotrophic factor (BDNF) expression. The compound does not bind serotonin transporters, norepinephrine transporters, dopamine transporters, or any of the receptor families (muscarinic, histaminergic, adrenergic, GABAergic, glutamatergic, opioid) that produce the common adverse-event signatures of the selective serotonin reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor, and tricyclic antidepressant classes, and consequently exhibits a tolerability profile characterized by the absence of sexual dysfunction, weight gain, discontinuation syndrome, and serotonin syndrome risk that distinguishes it from essentially all other antidepressant classes.

    Clinical efficacy in major depressive disorder has been established in multiple randomized, double-blind, placebo-controlled trials at the approved oral dose of 25 to 50 mg once daily at bedtime; pooled head-to-head analyses against fluoxetine, sertraline, venlafaxine, paroxetine, and escitalopram demonstrate broadly comparable antidepressant efficacy with superior tolerability and lower dropout rates. Relapse prevention has been demonstrated in a 24-week extension study with significantly lower cumulative relapse rate on agomelatine (24 percent) compared to placebo (50 percent). A separate clinical evidence base supports efficacy in generalized anxiety disorder, with randomized placebo-controlled trials demonstrating superiority on the Hamilton Anxiety Rating Scale and comparable efficacy to escitalopram with superior sleep restoration.

    Pharmacokinetics are dominated by extensive hepatic first-pass metabolism through cytochrome P450 1A2 (CYP1A2, accounting for approximately 90 percent of clearance) and CYP2C9/CYP2C19 (approximately 10 percent), producing an oral bioavailability of approximately 1 percent despite greater than 80 percent gastrointestinal absorption, a plasma elimination half-life of 1 to 2 hours, and high inter-individual variability driven principally by CYP1A2 activity. The major metabolites (3-hydroxy-agomelatine, 7-desmethyl-agomelatine, and 3-hydroxy-7-desmethyl-agomelatine) are pharmacologically inactive and are renally eliminated after conjugation. CYP1A2 induction by tobacco smoking reduces plasma concentrations three- to fourfold; strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) increase exposure by up to 60-fold and are contraindicated in concurrent use.

    The principal safety concern specific to agomelatine is dose-dependent hepatotoxicity, manifesting as transaminase elevation greater than three times the upper limit of normal in approximately 1.3 percent of patients at 25 mg daily and 2.5 percent at 50 mg daily. Serious hepatic reactions including cytolytic hepatitis and rare hepatic failure have been reported in postmarketing surveillance. Regulatory authorities require liver function testing before treatment initiation, at approximately 3, 6, 12, and 24 weeks of treatment, and at dose increase. Withdrawal of agomelatine leads to rapid normalization of transaminases in essentially all reported cases. The compound is contraindicated in patients with hepatic impairment.

    This monograph reviews the chemistry, synthesis, and structural pharmacology of agomelatine; the dual-receptor mechanism in molecular and circadian detail; the comprehensive human pharmacokinetic record including CYP1A2 polymorphism and drug interactions; the clinical evidence base across major depressive disorder, generalized anxiety disorder, and sleep-related indications; the preclinical pharmacology including circadian, neurogenic, and anti-stress mechanisms; sourcing and quality verification for research applications; reconstitution and handling; stack-interaction considerations; the hepatotoxicity signal and broader adverse-event profile; and a comparative assessment of five alternative compounds (melatonin, ramelteon, tasimelteon, mirtazapine, vortioxetine) against agomelatine on five competency standards. The compound is not approved by the United States Food and Drug Administration. It is sold as a research-grade preparation outside its marketed antidepressant application; investigators should obtain analytical confirmation of identity and purity on every lot.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-072Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • J-147

    Phenyl hydrazide neurotrophic compound targeting mitochondrial ATP synthase alpha-F1 subunit with geroprotective and neuroprotective activity

    A synthetic curcumin-derived phenyl hydrazide developed at the Salk Institute through phenotypic screening against multiple age-associated neurotoxicities, identified as a partial modulator of mitochondrial ATP synthase alpha subunit (ATP5A) that activates the CAMKK2/AMPK longevity axis, with robust preclinical neuroprotection and cognitive reversal in aged Alzheimer’s disease mice and advancement to Phase 1 clinical evaluation.

    Abstract

    J-147 (CAS 1146963-51-0; molecular formula C18H17F3N2O2; molecular weight 350.33) is a synthetic phenyl hydrazide small molecule developed at the Salk Institute for Biological Studies in the laboratory of David Schubert through iterative phenotypic optimization beginning from the natural product curcumin. First reported by Chen et al. in 2011, J-147 was selected from a combinatorial chemical library on the basis of nanomolar potency across six cell-based assays modeling age-associated neurotoxicities: trophic factor withdrawal (EC50 25 nM), oxidative stress (EC50 10 to 200 nM), glucose starvation, chemical ischemia, and amyloid-beta 1-42 toxicity. The compound represents approximately 100-fold greater potency than its immediate precursor CNB-001 and vastly greater potency and bioavailability than curcumin itself, which was inactive in the selection assays at achievable concentrations.

    The molecular target of J-147 was identified in 2018 by Goldberg et al. as the alpha-F1 subunit of mitochondrial ATP synthase (ATP5A), using drug affinity responsive target stability (DARTS) and biotinylated affinity precipitation approaches. J-147 partially inhibits ATP synthase activity with an EC50 of approximately 20 nM and saturates at approximately 23.6 percent inhibition, producing a dose-dependent increase in cytosolic calcium that activates calcium/calmodulin-dependent protein kinase kinase beta (CAMKK2), which phosphorylates AMP-activated protein kinase (AMPK) at threonine 172. The resulting AMPK activation modulates mammalian target of rapamycin complex 1 (mTORC1) signaling, acetyl-CoA carboxylase 1 (ACC1) activity, and downstream metabolic pathways linked to both aging and neurodegeneration. ATP5A knockdown phenocopies J-147 across multiple neuroprotection assays, and J-147 provides no additional protection in ATP5A-knockdown cells, confirming target engagement specificity.

    In preclinical models, J-147 administered orally at 200 ppm in food (approximately 10 mg/kg/day) prevents cognitive decline in young APP/swePS1-deltaE9 transgenic mice over 7 months, preserves synaptic proteins (drebrin, synapsin-1, synaptophysin), reduces soluble amyloid-beta 1-40 and 1-42, increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), facilitates long-term potentiation at concentrations of 0.01 to 1 micromolar, and reduces oxidative stress and neuroinflammation markers. In aged (20-month) APP/PS1 mice, 3 months of J-147 treatment reverses established cognitive deficits in water maze, fear conditioning, and elevated plus maze paradigms. In the SAMP8 senescence-accelerated mouse model, J-147 attenuates age-associated hippocampal transcriptional drift by approximately 6 percent (P less than 10 to the negative 10). In Drosophila melanogaster, J-147 extends median lifespan by 9.5 to 12.5 percent.

    Pharmacokinetically, J-147 demonstrates 28 percent oral bioavailability in mice, a plasma half-life of 1.5 hours, a brain half-life of 2.5 hours, brain concentrations of approximately 600 nM at 2 hours after a 20 mg/kg oral dose (5- to 10-fold above its neuroprotective EC50), and a brain-to-plasma ratio of approximately 0.5. The compound is classified as having high blood-brain barrier penetration by the MDCK-MDRI cell culture model. Safety evaluation demonstrates no genotoxicity (Ames test negative to 0.36 mM), no acute toxicity in rats at 2 g/kg, no hERG channel inhibition, a CeeTox predicted toxicity value of 90 micromolar (yielding a therapeutic safety window of 782 to 3600-fold over efficacy concentrations), and no significant off-target activity across more than 60 CNS receptors, 352 protein kinases, and extensive enzyme panels. The sole notable off-target interactions are modest dopamine transporter (EC50 0.649 micromolar) and monoamine oxidase B (EC50 1.88 micromolar) activities at concentrations 6.5- to 19-fold above the neuroprotective range. A Phase 1 randomized double-blind placebo-controlled clinical trial (NCT03838185) was initiated in February 2019 by Abrexa Pharmaceuticals and completed in February 2020; results have not been published. The compound is not approved by any regulatory authority and is supplied exclusively as a research compound.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-2095Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Navitoclax (ABT-263)

    Orally bioavailable BH3-mimetic inhibitor of anti-apoptotic BCL-2 family proteins (BCL-2, BCL-XL, BCL-W) with senolytic and anti-fibrotic activity

    A first-in-class orally bioavailable BH3-domain mimetic developed at Abbott Laboratories that binds BCL-2, BCL-XL, and BCL-W with sub-nanomolar affinity, inducing mitochondrial apoptosis in malignant and senescent cells, and now advancing in combination with ruxolitinib in myelofibrosis.

    Abstract

    Navitoclax (ABT-263) is an orally bioavailable, small-molecule BH3-domain mimetic that binds with sub-nanomolar affinity to three anti-apoptotic members of the B-cell lymphoma 2 (BCL-2) protein family: BCL-2 (Ki less than or equal to 1 nM), BCL-XL (Ki less than or equal to 0.5 nM), and BCL-W (Ki less than or equal to 1 nM). The compound was developed at Abbott Laboratories (now AbbVie) as an orally bioavailable successor to the intravenous-only BH3 mimetic ABT-737, retaining the high-affinity, multi-target BCL-2 family binding of the parent molecule while achieving moderate oral bioavailability suitable for chronic dosing. Navitoclax occupies the hydrophobic BH3-binding groove on anti-apoptotic BCL-2 family members, displacing sequestered pro-apoptotic effectors BAX and BAK and thereby triggering mitochondrial outer membrane permeabilization, cytochrome c release, caspase activation, and intrinsic apoptosis in cells dependent on BCL-2 or BCL-XL for survival.

    The compound entered oncology clinical development in 2007. Phase 1 studies in chronic lymphocytic leukemia (CLL) demonstrated substantial single-agent activity, with an objective response rate of 31 percent and durable responses (median progression-free survival 25 months) in relapsed or refractory disease [1]. Phase 1 and Phase 2 studies in small-cell lung cancer (SCLC) and other solid tumors demonstrated limited single-agent activity, with an objective response rate of 2.6 percent in relapsed SCLC [2]. Clinical development as a single-agent oncologic therapy was constrained by mechanism-based, dose-limiting thrombocytopenia arising from BCL-XL inhibition in circulating platelets, which depend on BCL-XL for survival [3]. This on-target platelet toxicity motivated the development of the BCL-2-selective derivative venetoclax (ABT-199), which retains potent BCL-2 inhibition while sparing BCL-XL and thereby avoiding thrombocytopenia; venetoclax received FDA approval for CLL in 2016 and has become the foundational BCL-2-targeted agent in hematologic oncology.

    Navitoclax has continued in clinical development in combination regimens. The Phase 3 TRANSFORM-1 trial of navitoclax combined with the JAK1/JAK2 inhibitor ruxolitinib in treatment-naive myelofibrosis met its primary endpoint, demonstrating a spleen volume reduction of 35 percent or greater (SVR35) at week 24 in 63.2 percent of patients on the combination compared with 31.5 percent on ruxolitinib plus placebo [4]. The Phase 3 TRANSFORM-2 trial in relapsed or refractory myelofibrosis is ongoing with anticipated completion in late 2026. These results position navitoclax as a potential first-in-class BCL-2 family inhibitor approved for myelofibrosis.

    A second major research application emerged in 2016 with the identification of navitoclax as a potent senolytic agent. Senescent cells, which accumulate with aging and after genotoxic stress, upregulate BCL-XL and other anti-apoptotic BCL-2 family members as part of the senescence-associated apoptosis-resistance program. Zhu et al. (2016) and Chang et al. (2016) demonstrated that navitoclax selectively eliminates senescent cells in vitro and in vivo, rejuvenating aged hematopoietic stem cells, clearing senescent muscle stem cells, and improving vascular function in aged mice [5, 6]. The compound has since been characterized as anti-fibrotic in preclinical models of idiopathic pulmonary fibrosis, where it induces apoptosis in fibroblasts overexpressing BCL-2 family members and reverses established fibrosis [7]. These findings have positioned navitoclax as the prototype research senolytic and a pharmacological tool for investigating the contribution of cellular senescence to aging, fibrosis, and degenerative disease.

    Pharmacokinetics in humans are characterized by slow oral absorption (time to peak concentration approximately 7 to 9 hours), a terminal elimination half-life of approximately 15 to 17 hours, high plasma protein binding (greater than 99 percent), and low volume of distribution (0.5 to 0.7 L/kg). The compound is metabolized by CYP3A4 and is a moderate inhibitor of CYP2C8 and a strong inhibitor of CYP2C9. Approximately 90 percent of the administered dose is excreted in feces, with approximately half as metabolites. A high-fat meal increases oral exposure by approximately 70 percent. The compound is not approved by any regulatory authority for any indication. It is available as a research-grade preparation from multiple chemical suppliers. Investigators should obtain analytical confirmation of identity and purity on every lot.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1643Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Acoramidis

    Selective transthyretin tetramer kinetic stabilizer designed to mimic the naturally occurring T119M protective variant

    A fluorinated benzoic acid derivative engineered to replicate the enthalpy-driven transthyretin stabilization of the protective T119M genetic variant, approved for transthyretin amyloid cardiomyopathy following a positive Phase 3 trial demonstrating reductions in all-cause mortality and cardiovascular hospitalization.

    Abstract

    Acoramidis (AG10) is a potent, selective, orally bioavailable small-molecule kinetic stabilizer of the transthyretin (TTR) tetramer, approved in the United States, European Union, United Kingdom, and Japan for the treatment of cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). The compound was rationally designed to replicate the molecular mechanism of the naturally occurring T119M variant of TTR, a protective mutation that stabilizes the tetramer against the rate-limiting dissociation step that initiates amyloid fibril formation. Structurally, acoramidis is a 3,5-dimethylpyrazole linked through a propyloxy tether to a 4-fluorobenzoic acid; the pyrazole ring forms two hydrogen bonds with serine 117 and serine 117 prime residues at the floor of the thyroxine binding pocket, replicating the inter-dimer contact created by the threonine-to-methionine substitution in T119M carriers. This enthalpy-driven binding mechanism (binding enthalpy of negative 13.6 kilocalories per mole, compared to negative 5.0 kilocalories per mole for tafamidis) underpins the high selectivity of acoramidis for TTR over albumin and its capacity to achieve greater than 90 percent tetramer stabilization across the entire dosing interval at steady state. The clinical development program for acoramidis established pharmacokinetic parameters favorable for twice-daily oral dosing: rapid absorption (time to peak concentration less than one hour), terminal elimination half-life of approximately 25 hours, metabolism principally by UGT-mediated glucuronidation rather than cytochrome P450 enzymes, and renal elimination of conjugated metabolites. The pivotal Phase 3 ATTRibute-CM trial randomized 632 patients with wild-type or hereditary ATTR-CM to acoramidis 800 milligrams (as the hydrochloride salt) twice daily or placebo for 30 months. On the primary hierarchical endpoint (a four-component analysis of all-cause mortality, cardiovascular-related hospitalization, NT-proBNP change, and six-minute walk distance), acoramidis demonstrated a win ratio of 1.8 (95 percent confidence interval 1.4 to 2.2; P less than 0.001). The time-to-event composite of all-cause mortality or first cardiovascular hospitalization favored acoramidis with a hazard ratio of 0.64 (95 percent confidence interval 0.50 to 0.83; P equals 0.0008), with Kaplan-Meier curves separating at three months and benefit sustained through 42 months of follow-up in the open-label extension. A cardiac magnetic resonance substudy demonstrated stabilization of left ventricular mass and improvement of ejection fraction in the acoramidis arm relative to progressive deterioration in placebo recipients. The adverse event profile was similar to placebo; diarrhea (11.6 versus 7.6 percent) and gout (10.9 versus 8.1 percent) were the most frequent treatment-emergent events occurring at higher rates with acoramidis. This monograph reviews the chemistry, synthesis, and rational design of acoramidis; the enthalpy-driven TTR stabilization mechanism characterized through isothermal titration calorimetry and X-ray crystallography; the complete human pharmacokinetic profile; preclinical pharmacology in rodent and canine models; the clinical evidence base from Phase 1 through Phase 3 and the open-label extension; sourcing and quality considerations for research applications; reconstitution and handling; metabolic and pharmacodynamic interactions; the adverse event and safety profile; and a comparative assessment of five transthyretin-directed therapies (tafamidis, diflunisal, patisiran, vutrisiran, and eplontersen) against acoramidis on five competency standards. Acoramidis is a prescription medicine in its approved jurisdictions and is available as a research-grade preparation for investigational applications outside the approved indication. Investigators should obtain analytical confirmation of identity and purity on every research-grade lot.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1660Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.